Penicillin and Streptomycin Market Growth, Size, Share and Forecast 2019-2025

Global penicillin and streptomycin market is expected to grow with a CAGR of 0.3% during the forecast period. Penicillin and streptomycin are defined as a class of antibiotics that are used to kill bacterial infection and restrict bacterial growth. World Health Organization (WHO) included it in its list of essential medicines which are the most effective and safe medicines that are required in the healthcare system. Penicillin has been significantly used to treat infection, meningitis and so on. Streptomycin has been significantly used for the treatment of tuberculosis. Rising use of antibiotics in cell culture is offering an opportunity for the growth of the market. Antibiotics are frequently added to cell culture media as it suppresses contamination. The most common antibiotics for the cultivation of cells include a combination of penicillin and streptomycin. Many cell culture laboratories routinely add antibiotics and antimycotics to all cell culture media during the establishment of a primary culture, or while propagating specific valuable stocks or to eliminate any contamination.

A full report of Global Penicillin and Streptomycin Market is available at: https://www.omrglobal.com/industry-reports/penicillin-and-streptomycin-market

Several pharmaceutical companies have started to specifically introduce penicillin and streptomycin solutions for cell culture applications, such as Lonza AG and Thermo Fisher Scientific, Inc. Thermo Fisher Scientific, Inc. offers an antibiotic solution that contains Penicillin-Streptomycin-Glutamine and µg/mL of streptomycin that are used to prevent bacterial contamination of cell cultures due to their efficient combined action against gram-negative and gram-positive bacteria. As the cell culture researches are growing significantly, the demand for penicillin and streptomycin in cell culture is anticipated to grow in the near future. However, patent expiration and availability of substitute products are creating hurdles in the growth of the market.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/penicillin-and-streptomycin-market

Segment Outlook

The global penicillin and streptomycin market are segmented on the basis of product, manufacturing process, route of administration, and end-user. Based on the product, the market is further classified into penicillin and streptomycin. Based on the manufacturing process, the market is further segmented into natural, synthesis, and semi-synthesis process. Based on the route of administration, the market is further segmented into oral, intramuscular, and intravenous. Based on end-user, the market is further segmented into hospitals, clinics, and others.

Global Penicillin and Streptomycin Market: By Product

Penicillin is anticipated to hold the major share in 2018 due to significant demand for penicillin for the treatment of bacterial infections, such as ear infections, skin infections, and urinary tract infection. It works to kill and prevent the growth of bacteria. In addition, the shortage of penicillin was reported due to the rising prevalence of infectious diseases which created significant demand for penicillin in the global market. According to the WHO, the shortage of Benzathine Penicillin G (BPG) occurred which is the only recommended treatment to prevent mother-to-child transmission of syphilis. Among sexually transmitted diseases (STD), syphilis is unique that can be curable with a penicillin single dose. According to WHO, 930,000 pregnant women annually have probable active syphilis (transmissible during pregnancy) which results in nearly 350,000 adverse birth outcomes, such as organ deformities and prematurity annually. Of 114 countries, 95 countries (41%) reported a shortage of BPG and 56 (59%) reported no BPG shortage during the period, 2014-2016. The drug is sold at a very low cost. As per Clinton Health Access Initiative (CHAI) estimation, BPG is sold on average at a cost of $0.11 for a 1.2 million international unit (IU) dose and $0.20 for 2.4 million IU does in low-and-middle-income countries. However, some countries set an additional cap on the price at which the drug can be sold that also keep the price low. This, in turn, shows a rising demand for penicillin for the treatment and prevention of infectious disease. However, the shortage of these drugs may also a major restraining factor for the market growth which would result in shifting towards other antibiotic alternatives, such as erythromycin, amoxicillin, and ceftriaxone.

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/penicillin-and-streptomycin-market

Global Penicillin and Streptomycin Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Abbott Laboratories, Inc.
• Alembic Pharmaceuticals, Ltd.
• Astellas Pharma, Inc.
• Bayer AG
• Biogen International GmbH
• Bristol-Myers Squibb Co.
• Corden Pharma GmbH
• Eli Lilly & Co.
• F. Hoffmann La Roche, Ltd.
• GlaxoSmithKline PLC
• Jiangxi Dongfeng Pharmaceutical Co., Ltd.
• Lonza AG
• Merck & Co., Inc.
• MODASA Pharmaceuticals Pvt. Ltd.
• Novartis AG
• Pfizer, Inc.
• Sanofi-Aventis Group
• Takeda Pharmaceutical Co., Ltd.
• Thermofisher Scientific, Inc.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

This release was published on openPR.